Home » Stocks » ITOS

iTeos Therapeutics, Inc. (ITOS)

Stock Price: $26.80 USD -1.77 (-6.20%)
Updated November 30, 2:36 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 939.20M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 35.04M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 30
Last Price $26.80
Previous Close $28.57
Change ($) -1.77
Change (%) -6.20%
Day's Open 28.22
Day's Range 26.50 - 29.00
Day's Volume 202,341
52-Week Range 17.57 - 32.92

More Stats

Market Cap 939.20M
Enterprise Value 599.09M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 35.04M
Float n/a
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 353,526
Short Ratio 3.26
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.98
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 340.11M
Net Cash / Share 9.70
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 4
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(62.69% upside)
Current: $26.80
Target: 43.60
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-28.05-21.50
Net Income-22.45-18.06
Shares Outstanding0.670.62
Earnings Per Share-39.51-32.63
Operating Cash Flow-23.15-19.10
Capital Expenditures-0.72-0.23
Free Cash Flow-23.87-19.32
Cash & Equivalents19.9922.05
Net Cash / Debt19.9922.05
Book Value-36.09-10.68
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name iTeos Therapeutics, Inc.
Country United States
Employees 55
CEO Michel Detheux

Stock Information

Ticker Symbol ITOS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ITOS
IPO Date July 24, 2020


Iteos Therapeutics, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.